Sagimet Biosciences Inc. Files 8-K on Financials
Ticker: SGMT · Form: 8-K · Filed: Nov 14, 2024 · CIK: 1400118
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
TL;DR
Sagimet Biosciences filed an 8-K on Nov 14 detailing financial results and condition.
AI Summary
Sagimet Biosciences Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial status. Sagimet Biosciences Inc. is incorporated in Delaware and its principal executive offices are located in San Mateo, California.
Why It Matters
This 8-K filing provides investors with crucial updates on Sagimet Biosciences Inc.'s financial performance and condition, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Sagimet Biosciences Inc. (company) — Registrant
- November 14, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Mateo, California (location) — Address of principal executive offices
- 3-V Biosciences, Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Sagimet Biosciences Inc.'s results of operations and financial condition, including financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on November 14, 2024.
In which state is Sagimet Biosciences Inc. incorporated?
Sagimet Biosciences Inc. is incorporated in Delaware.
What is the address of Sagimet Biosciences Inc.'s principal executive offices?
The address of Sagimet Biosciences Inc.'s principal executive offices is 155 Bovet Road, Suite 303, San Mateo, California 94402.
What was Sagimet Biosciences Inc.'s former company name?
Sagimet Biosciences Inc.'s former company name was 3-V Biosciences, Inc.
Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-11-14 08:05:19
Key Financial Figures
- $0.0001 — ich registered Series A Common Stock, $0.0001 par value per share SGMT The Nasdaq G
Filing Documents
- tm2428394d1_8k.htm (8-K) — 28KB
- tm2428394d1_ex99-1.htm (EX-99.1) — 66KB
- tm2428394d1_ex99-1img001.jpg (GRAPHIC) — 22KB
- 0001104659-24-118342.txt ( ) — 304KB
- sgmt-20241114.xsd (EX-101.SCH) — 3KB
- sgmt-20241114_lab.xml (EX-101.LAB) — 33KB
- sgmt-20241114_pre.xml (EX-101.PRE) — 22KB
- tm2428394d1_8k_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 99.1 Press Release of Sagimet Biosciences Inc., dated November 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: November 14, 2024 By: /s/ David Happel David Happel Chief Executive Officer